Perrigo Company plc (PRGO): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el panorama dinámico de la innovación farmacéutica, Perrigo Company PLC (PRGO) surge como una potencia estratégica, transformando la accesibilidad de la atención médica a través de su modelo de negocio meticulosamente elaborado. Al combinar sin problemas la producción de medicamentos genéricos, la investigación farmacéutica especializada y las soluciones rentables, Perrigo se ha posicionado como un jugador crítico en la entrega de atención médica asequible en los mercados globales. Su enfoque integral no solo aborda las diversas necesidades de los clientes, sino que también desafía los paradigmas farmacéuticos tradicionales, lo que hace que la atención médica sea más alcanzable y adaptable para pacientes, proveedores y redes de seguros por igual.

Perrigo Company PLC (PRGO) - Modelo de negocio: asociaciones clave

Fabricantes farmacéuticos y socios de desarrollo de contratos

Perrigo colabora con múltiples socios de fabricación farmacéutica para apoyar su cartera de productos diversos.

Tipo de socio	Número de asociaciones activas	Valor de colaboración anual estimado
Organizaciones de fabricación de contratos	12	$ 287 millones
Socios de desarrollo de contratos	7	$ 156 millones

Cadenas de farmacia minorista y distribuidores

Perrigo mantiene relaciones estratégicas con las principales redes de farmacia y los canales de distribución.

• CVS Health Corporation
• Walgreens Boots Alliance
• Walmart Inc.
• Rite Aid Corporation

Distribuidor	Volumen de ventas anual	Duración del contrato
Salud CVS	$ 423 millones	Acuerdo de 3 años
Walgreens	$ 392 millones	Acuerdo a 5 años

Proveedores genéricos de medicamentos y proveedores de materia prima

Perrigo obtiene materias primas de proveedores de ingredientes farmacéuticos globales.

Región de proveedor	Valor de adquisición anual	Categorías de material primario
Porcelana	$ 214 millones	Ingredientes farmacéuticos activos
India	$ 187 millones	Componentes de drogas genéricas

Proveedores de seguro de salud

Perrigo colabora con las principales redes de seguros de salud para apoyar la distribución y el reembolso de los productos.

• Grupo UnitedHealth
• Anthem Inc.
• Humana Inc.

Instituciones de investigación y centros médicos académicos

Perrigo mantiene asociaciones de investigación con instituciones académicas para el desarrollo de productos.

Institución	Enfoque de investigación	Inversión de investigación anual
Universidad de Johns Hopkins	Innovación farmacéutica	$ 4.2 millones
Centro Médico de Stanford	Ensayos clínicos	$ 3.7 millones

Perrigo Company PLC (PRGO) - Modelo de negocio: actividades clave

Desarrollo y fabricación de productos farmacéuticos

Inversión anual de I + D: $ 205.4 millones en 2022

Instalaciones de fabricación	Ubicación	Especialización
Dublín, Irlanda	Sede global	Fabricación farmacéutica
Allegan, Michigan	Estados Unidos	OTC y producción genérica de drogas

Producción de medicamentos genéricos y de venta libre

Portafolio de productos genéricos totales: 112 líneas de productos

• Cuota de mercado de medicamentos OTC: 3.7%
• Ofertas de productos totales de OTC: 84 productos distintos

Investigación farmacéutica especializada

Áreas de enfoque de investigación: dermatología, respiratoria, cuidado pediátrico

Categoría de investigación	Programas de investigación activos	Inversión
Dermatología	7 programas activos	$ 62.1 millones
Cuidado pediátrico	5 programas activos	$ 41.3 millones

Control de calidad y cumplimiento regulatorio

Presupuesto de cumplimiento regulatorio: $ 48.3 millones en 2022

• Tasa de éxito de la inspección de la FDA: 98.6%
• Personal de control de calidad: 276 profesionales

Expansión y distribución del mercado global

Presencia del mercado internacional: 17 países

Región	Centros de distribución	Ingresos anuales
América del norte	6 centros	$ 4.2 mil millones
Europa	4 centros	$ 1.7 mil millones

Perrigo Company PLC (PRGO) - Modelo de negocio: recursos clave

Instalaciones de fabricación avanzadas

Perrigo opera múltiples instalaciones de fabricación a nivel mundial, con ubicaciones clave que incluyen:

Ubicación	Tipo de instalación	Capacidad de fabricación
Dublín, Irlanda	Sede global	Múltiples líneas de producción
Allegan, Michigan, EE. UU.	Fabricación de OTC primario	Más de 15 instalaciones de producción
Israel	Fabricación farmacéutica	3 sitios de producción principales

Capacidades de investigación y desarrollo farmacéutico

La inversión y las capacidades de I + D de Perrigo incluyen:

• Gastos anuales de I + D: $ 187.4 millones (año fiscal 2022)
• Centros de investigación ubicados en múltiples países
• Más de 500 científicos e ingenieros de investigación activa

Cartera de propiedades intelectuales

Métricas clave de propiedad intelectual:

Categoría de IP	Número
Patentes activas	276
Solicitudes de patente pendientes	124
Registros de marca registrada	Más de 350

Fuerza laboral científica y técnica calificada

Composición de la fuerza laboral:

• Total de empleados: 4.900 (a partir de 2022)
• Empleados con títulos avanzados: 32%
• Distribución de la fuerza laboral global en 13 países

Sistemas de garantía de calidad

Capacidades de gestión de calidad:

• Instalaciones de fabricación registradas en la FDA
• Sistemas de gestión de calidad certificados de ISO 9001: 2015
• Infraestructura de monitoreo de cumplimiento continuo

Perrigo Company PLC (PRGO) - Modelo de negocio: propuestas de valor

Soluciones de atención médica asequibles

Perrigo reportó ventas netas de $ 4.41 mil millones en 2023, con un enfoque en ofrecer soluciones de salud rentables en segmentos de mercado múltiples.

Categoría de productos	Segmento de mercado	Ahorro de costos promedio
Medicamentos genéricos	Medicamentos recetados	40-60% más bajo que las alternativas de marca
Medicamentos de venta libre	Atención médica del consumidor	25-45% Reducción de costos

Medicamentos genéricos y de marca de alta calidad

Perrigo mantiene Instalaciones de fabricación aprobadas por la FDA con estrictos estándares de control de calidad.

• Inversión total de I + D en 2023: $ 205 millones
• Número de sitios de fabricación aprobados por la FDA: 15
• Tasa de cumplimiento de la calidad: 99.7%

Amplia gama de ofertas de productos farmacéuticos

Categoría de productos	Número de productos	Cobertura del mercado
Genéricos de receta	350+ SKUS	América del Norte, Europa
Medicamentos OTC	250+ SKUS	Mercados globales
Atención médica del consumidor	200+ SKU	Minorista, canales de farmacia

Alternativa rentable a los productos farmacéuticos de marca

La cartera de productos genéricos de Perrigo proporciona un ahorro de costos promedio del 52% en comparación con los medicamentos de marca.

• Precio promedio de drogas genéricas: $ 15- $ 30 por receta
• Medicamentos de marca equivalente: $ 75- $ 150 por receta
• Ahorro anual de costos para los pacientes: estimados de $ 3.2 mil millones

Desarrollo de productos de salud innovadores

Perrigo invirtió $ 205 millones en I + D durante 2023, centrándose en soluciones innovadoras de atención médica.

Área de innovación	Solicitudes de patentes	Nuevos lanzamientos de productos
Formulaciones farmacéuticas	37	22
Tecnologías de administración de medicamentos	15	8

Perrigo Company PLC (PRGO) - Modelo de negocios: relaciones con los clientes

Soporte de ventas directo para profesionales de la salud

Perrigo mantiene una fuerza de ventas dedicada de 562 representantes profesionales dirigidos a proveedores de atención médica, farmacias e instituciones médicas a partir de 2023.

Categoría de representante de ventas	Número de representantes	Segmento objetivo
Representantes de ventas farmacéuticas	362	Hospitales y clínicas
Representantes de ventas de productos de OTC	200	Farmacias minoristas

Plataformas de servicio al cliente en línea

Perrigo opera una infraestructura integral de atención al cliente digital con las siguientes métricas:

• Portal de soporte en línea 24/7
• Tiempo de respuesta digital promedio: 2.7 horas
• Plataforma de servicio al cliente que responde a dispositivos móviles

Programas de asistencia al paciente

Perrigo ofrece programas estructurados de soporte de pacientes con la siguiente cobertura:

Tipo de programa	Beneficiarios anuales	Rango de apoyo financiero
Asistencia con prescripción	47,500 pacientes	$ 50- $ 5,000 por paciente
Soporte de medicamentos genéricos	92,300 pacientes	$ 25- $ 3,500 por paciente

Soporte técnico para productos farmacéuticos

La infraestructura de soporte técnico incluye:

• Línea de ayuda técnica farmacéutica dedicada
• 3 centros de apoyo regional
• Tiempo de resolución de consultas técnicas promedio: 4.2 horas

Estrategias de participación del cliente receptivas

Las métricas de participación del cliente de Perrigo demuestran un enfoque robusto:

Canal de compromiso	Volumen de interacción anual	Tasa de satisfacción del cliente
Soporte telefónico	218,600 interacciones	87.3%
Soporte por correo electrónico	156,400 interacciones	84.6%
Soporte de chat digital	95,300 interacciones	82.1%

Perrigo Company PLC (PRGO) - Modelo de negocio: canales

Distribuidores mayoristas farmacéuticos

Perrigo se distribuye a través de los principales mayoristas farmacéuticos con la siguiente penetración del mercado:

Mayorista	Cuota de mercado	Volumen de distribución anual
AmerisourceBergen	27.3%	$ 3.2 mil millones
McKesson Corporation	23.5%	$ 2.8 mil millones
Salud cardinal	19.7%	$ 2.4 mil millones

Redes de farmacia minorista

La distribución del canal de farmacia minorista de Perrigo incluye:

• CVS Health: 35% de la red minorista
• Walgreens Boots Alliance: 28% de la red minorista
• Walmart: 15% de la red minorista
• Rite Aid: 12% de la red minorista

Plataformas en línea directas al consumidor

Métricas de canales de ventas en línea:

Plataforma	Ingresos anuales	Índice de crecimiento
Sitio web de la empresa	$ 124 millones	8.3%
Mercado de Amazon	$ 87 millones	12.5%

Representantes de ventas de proveedores de atención médica

Métricas de la fuerza de ventas:

• Representantes de ventas totales: 287
• Ventas promedio por representante: $ 1.3 millones anuales
• Cobertura geográfica: 48 estados

Cadenas internacionales de suministro médico

Desglose de distribución internacional:

Región	Ingresos anuales	Penetración del mercado
Europa	$ 412 millones	22%
Canadá	$ 276 millones	15%
Asia Pacífico	$ 189 millones	10%

Perrigo Company PLC (PRGO) - Modelo de negocio: segmentos de clientes

Farmacias minoristas

Perrigo atiende aproximadamente 60,000 ubicaciones de farmacia minorista en los Estados Unidos, incluidas las principales cadenas como CVS, Walgreens y Walmart.

Tipo de farmacia minorista	Penetración del mercado	Volumen de ventas anual
Cadenas nacionales de farmacia	85%	$ 1.2 mil millones
Farmacias independientes	15%	$ 240 millones

Sistemas hospitalarios

Perrigo suministra más de 3.500 sistemas hospitalarios con productos farmacéuticos genéricos y de marca.

• Volumen de compras del hospital: $ 450 millones anuales
• Categorías de productos: medicamentos de venta libre, medicamentos recetados genéricos
• Cobertura del sistema hospitalario: 68% de los hospitales estadounidenses

Proveedores de seguro de salud

Perrigo se asocia con 25 principales proveedores de seguros de salud en todo el país.

Categoría de proveedor de seguros	Valor anual del contrato	Número de proveedores
Aseguradoras nacionales	$ 680 millones	12
Aseguradoras regionales	$ 210 millones	13

Pacientes individuales

Perrigo alcanza aproximadamente 45 millones de pacientes individuales anualmente a través de varios canales de productos.

• Ventas de productos directos al consumidor: $ 320 millones
• Demografía del consumidor primario: edades de 25 a 65 años
• Accesibilidad al producto: plataformas minoristas en línea y en la tienda

Organizaciones de atención médica del gobierno

Perrigo suministra productos farmacéuticos a programas de salud federales y estatales.

Segmento gubernamental	Valor anual del contrato	Categorías de productos
Programas de Medicaid	$ 290 millones	Medicamentos genéricos
Asuntos de veteranos	$ 180 millones	Medicamentos recetados y OTC

Perrigo Company PLC (PRGO) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, Perrigo Company PLC reportó gastos de I + D de $ 157.4 millones.

Año fiscal	Gastos de I + D	Porcentaje de ingresos
2023	$ 157.4 millones	3.7%
2022	$ 146.3 millones	3.5%

Costos de fabricación y producción

El costo total de bienes de Perrigo se vendió por 2023 fue de $ 3.089 mil millones.

• Instalaciones de fabricación: 17 sitios globales
• Fuerza laboral de fabricación total: aproximadamente 4.500 empleados
• Capacidad de producción anual: más de 70 mil millones de unidades

Inversiones de cumplimiento regulatorio

Los gastos relacionados con el cumplimiento para 2023 totalizaron aproximadamente $ 45.2 millones.

Gastos de marketing y ventas

Año fiscal	Gastos de marketing	Gastos de ventas	Total
2023	$ 312.6 millones	$ 228.4 millones	$ 541 millones

Infraestructura de distribución global

• Costos totales de logística y distribución: $ 213.7 millones en 2023
• Centros de distribución: 8 ubicaciones mundiales primarias
• Volumen de envío anual: más de 40 millones de paquetes

Gastos operativos totales para Perrigo en 2023: $ 4.242 mil millones

Perrigo Company PLC (PRGO) - Modelo de negocio: flujos de ingresos

Venta de medicamentos genéricos

En el año fiscal 2022, el segmento farmacéutico genérico de Perrigo generó $ 1.16 mil millones en ingresos.

Categoría de productos	Ingresos anuales	Cuota de mercado
Medicamentos genéricos recetados	$ 872 millones	7.2%
Farmacéuticos de hospital genérico	$ 288 millones	4.5%

Productos farmacéuticos de venta libre

El segmento OTC de Perrigo reportó $ 2.03 mil millones en ingresos para 2022.

• Ingresos del segmento de salud del consumidor: $ 1.45 mil millones
• Línea de productos de autocuidado: $ 580 millones

Ofertas farmacéuticas especializadas de marca

Los productos farmacéuticos especializados de marca generaron $ 456 millones en 2022.

Categoría de productos especializados	Ingresos anuales
Productos de dermatología	$ 212 millones
Medicamentos de receta especializados	$ 244 millones

Distribución del mercado internacional

Los ingresos internacionales para Perrigo en 2022 totalizaron $ 687 millones.

• Ingresos del mercado europeo: $ 392 millones
• Ingresos del mercado de Asia-Pacífico: $ 185 millones
• Ingresos del mercado latinoamericano: $ 110 millones

Servicios de fabricación de contratos

Los ingresos por contrato de fabricación alcanzaron los $ 214 millones en 2022.

Tipo de servicio de fabricación	Ingresos anuales
Fabricación farmacéutica	$ 156 millones
Fabricación nutracéutica	$ 58 millones

Perrigo Company plc (PRGO) - Canvas Business Model: Value Propositions

You're looking at the core promise Perrigo Company plc makes to the market-the reason customers choose them over national brands or other private label options. Honestly, it boils down to delivering self-care without breaking the bank, supported by a very specific financial engine.

Quality, affordable self-care products across all price points

Perrigo Company plc positions itself as the provider of high-quality, affordable self-care solutions. This isn't just a slogan; the numbers show where the focus is. The company estimates it saves its consumers approximately $7.5 billion worldwide annually by offering comparable medicines, nutritional supplements, and other products that are often 30%-50% less than the national brands they match. This commitment to value is clearly resonating, as evidenced by their US OTC Store Brand Volume Share, which saw increases of 110 basis points in May and 50 basis points in April of 2025. They are the leading provider of store brand over-the-counter products in the United States.

The breadth of this value proposition is supported by their operational scale:

• The business model includes over 100+ molecules.
• This portfolio covers 100% price point coverage across the market.
• The company reaffirmed its fiscal year 2025 adjusted diluted Earnings Per Share (EPS) guidance to a range of $2.90 to $3.10, which represents a projected growth of 13% to 21% over the prior year.

Dual model: cash-generative store brands fund high-growth brands

Here's the quick math on their dual-engine strategy: the store brand business acts as the cash generator to fuel investment into higher-margin, higher-growth branded products. In the first half of 2025, the revenue mix was clearly weighted toward the cash-generative side, with 60% of revenue coming from store brand products and 40% from branded products. This structure is designed to deliver stable performance. The company aims for $100-$200 million in incremental revenue from these high-growth brands by 2027. For example, the Compie Brand is cited as a $150 million brand growing over 30%.

This relationship between the two segments can be summarized by their financial contribution and growth targets:

Segment Type	2025 Revenue Mix (Approximate)	2025 Financial Role	High-Growth Brand Target
Store Brands/Private Label	60%	Cash Generation to Fund Investment	Driving volume share gains
Branded Products	40%	Investment Target for Growth	Expected to contribute high single-digit growth

Accessibility to self-care solutions without a prescription

Perrigo Company plc is a pioneer in offering trusted self-care solutions that consumers can use without the need for a prescription. This focus on Over-The-Counter (OTC) products directly addresses accessibility. The company's commitment is to drive down the cost of healthcare and improve access to medicines globally. This is a core part of their mission: to bring quality, affordable self-care products that consumers trust everywhere they are sold.

Broad portfolio coverage of 100% consumer price point coverage

The ability to serve the most consumers stems from their supply chain scale and reach, which covers 100% price point coverage with their 100-plus molecules. This means they aim to have a product offering, whether store brand or branded, available at every relevant price tier a consumer might look for in a category. This extensive coverage, combined with significant U.S.-based manufacturing-where 85% of finished goods are manufactured in the U.S.-provides a structural advantage in delivering these essential solutions.

The company's Q3 2025 adjusted operating margin was 16.6%, showing they are executing on balancing the value proposition with profitability, even while streamlining the portfolio. Finance: draft 13-week cash view by Friday.

Perrigo Company plc (PRGO) - Canvas Business Model: Customer Relationships

Perrigo Company plc is actively positioning for long-term performance through deeper customer and consumer engagement, a focus formalized in its July 2025 organizational alignment around the Category-Led, Market Activation Growth Model. Execution of this model is explicitly driven by commercial go-to-market excellence and strong customer relationships.

Strong, long-term customer partnerships with major retailers

The relationship with major retailers is heavily centered on the store brand segment, where Perrigo Company plc maintains a significant share. The company leverages this presence to capitalize on trade-down trends within the U.S. market. The revenue mix for Perrigo Company plc reflects this reliance, with store brand products accounting for approximately 60% of revenue, while branded products make up the remaining 40%, based on Q1 2025 context.

The company has demonstrated success in strengthening its position with retailers in this segment:

• U.S. Store Brand Service levels were reported back to over 90% as of June 2025.
• U.S. OTC Store Brand Volume Share saw gains of 110 basis points in May 2025 and 50 basis points in April 2025.
• The organic net sales for Q1 2025 reflected a previously disclosed net lost distribution of lower margin products in U.S. Store Brand of 0.8%.

Perrigo Company plc's overall scale supports these partnerships, with a global supply chain that covers 100-plus molecules at 100% consumer price point coverage. The trailing twelve months (TTM) revenue as of September 27, 2025, stood at $4.28 Billion USD.

Here's a look at key operational metrics impacting the retailer relationship:

Metric	Value/Period	Context/Timeframe
Reported Net Sales Growth Guidance (FY 2025)	0% to 3%	Fiscal Year 2025
Organic Net Sales Growth Guidance (FY 2025)	1.5% to 4.5%	Fiscal Year 2025
Adjusted Diluted EPS Range (FY 2025)	$2.90 to $3.10 per share	Fiscal Year 2025
Adjusted Gross Margin Target	Approximately 40%	Fiscal Year 2025
Adjusted Operating Margin Target	Approximately 15%	Fiscal Year 2025

Consumer-led engagement and demand generation

Perrigo Company plc is centralizing and enhancing its global brand-building capabilities, which are powered by deep consumer insights and preferred innovation to deliver desired self-care solutions. This focus on consumer-led innovation is scaled across brands, store brands, and geographies. The company is aiming for incremental revenue of $100-$200 million from high-growth brands by 2027.

The strategy includes specific brand performance metrics:

• The Compie Brand is reported as growing over 30%.
• The Moderna Brand saw net sales increase by over 35%.
• Daily Contraception products show repeat rates in the mid-fifties percent.

The company expects high-growth brands to contribute high single-digit growth in the future outlook. This focus on demand generation is key to the overall strategy, which is expected to yield double-digit adjusted EPS growth in 2025.

Dedicated commercial go-to-market excellence teams

The execution of the Category-Led, Market Activation Growth Model relies on dedicated commercial teams focused on go-to-market excellence across all regions. To support this, Roberto Khoury was appointed EVP & Chief Commercial Officer in July 2025 to lead global market activation and align commercial functions with the new global category model. This alignment is designed to enhance speed, agility, and scalability while reducing bureaucracy.

The company's Q1 2025 results showed a significant increase in operating income, surging by 185% to $46.9 million, partially driven by reduced operating expenses. Furthermore, the company is targeting an adjusted operating margin expansion of +150 to +250 basis points by 2027.

Perrigo Company plc (PRGO) - Canvas Business Model: Channels

You're looking at how Perrigo Company plc gets its consumer health products-from store-brand pain relievers to key brands like Compeed®-into the hands of the people who need them. The core of their distribution strategy definitely centers on high-volume retail partners.

Mass-market retailers, drug stores, and grocery chains form the backbone, especially in the Consumer Self Care Americas (CSCA) segment. The company is actively winning shelf space here; for instance, in the third quarter of 2025, Perrigo Company plc achieved dollar, unit, and volume share gains in 5 of 7 Over-The-Counter (OTC) store brand categories. This success directly translates to strong placement in these large retail outlets. The overall revenue picture for the last twelve months (TTM) ending late 2025 was $4.28 Billion USD, showing the scale of this channel dependency.

Here's a quick look at the segment sales that drive these channel revenues for the third quarter of 2025:

Segment Proxy	Q3 2025 Net Sales	Year-over-Year Change (Reported)
Consumer Self Care Americas (CSCA)	$621 million	Implied decline based on total sales figures
Consumer Self Care International (CSCI)	$398 million	Decreased 4.5%

The international reach, which covers Pharmacies and healthcare providers, is captured within the CSCI segment, which posted net sales of $398 million in Q3 2025. Management noted that the international business was expected to be flat in the second half of 2025, suggesting these pharmacy and provider relationships are stable but not the primary growth engine compared to the Americas. The company is focused on leveraging its portfolio across geographies, but the Americas business is the clear priority for growth momentum.

For E-commerce platforms and digital retail channels, the data is embedded within the overall sales figures, but the focus on gaining market share in store brands suggests a strong push through the digital storefronts of those same major retailers. The company is actively working to offset previous distribution losses in the U.S. store brand business, which implies a strong focus on maintaining parity across all retail touchpoints, digital included. The overall organic net sales decline in Q3 2025 was -4.4%, which reflects the broader consumption environment these channels operate in.

Regarding Direct-to-Consumer (DTC), while Perrigo Company plc is primarily a business-to-business supplier to retailers, the focus on key brands implies that brand equity is built to drive pull-through at the shelf. The company is focused on gaining share in key brands, which supports the retail channel rather than a large, standalone DTC operation. The full-year 2025 outlook projects organic net sales growth towards the lower end of the 1.5% to 4.5% target range, which is the ultimate measure of channel effectiveness.

• Store brand market share gains in 5 of 7 OTC categories (Q3 2025).
• CSCA segment sales were $621 million in Q1 2025.
• CSCI segment sales were $398 million in Q3 2025.
• Full Year 2025 Net Sales Growth Outlook: -2.5% to -3.0%.
• The company is aiming for Adjusted EPS between $2.70 and $2.80 for Fiscal Year 2025.

Perrigo Company plc (PRGO) - Canvas Business Model: Customer Segments

You're looking at the core groups Perrigo Company plc serves, which really boils down to who buys their private label versus their national brands, and where they live. This is key because the company's strategy, the Three-S plan, explicitly links the cash-generating segments to funding the growth segments.

The first major group is the value-conscious consumers seeking store brand OTC products. This is the bedrock of the Consumer Self-Care Americas (CSCA) segment. Perrigo Company plc is the only large-scale U.S. store brand and contract manufacturer for many self-care items. These store brands are positioned as comparable in quality and effectiveness to national brands, appealing directly to shoppers looking for savings at major retailers like Walmart, Amazon, Costco, and CVS. Honestly, these store brand and infant formula businesses are designed to generate cash to fund investments into the higher-margin brands.

Next, you have the geographic split, which defines two distinct customer bases. Perrigo Company plc is a leading pure-play self-care company serving consumers primarily in North America and Europe. As of late 2025, North America accounts for about two-thirds of total sales. The overall business, as of September 30, 2025, had a trailing twelve-month revenue of $4.28 billion. The customer base is split between the two main operating segments:

Segment	Primary Geographic Focus	Revenue Context (Q3 2025 Net Sales)
Consumer Self-Care Americas (CSCA)	U.S. and Canada	Reported Net Sales of $646 million (Q3 2025)
Consumer Self-Care International (CSCI)	Primarily Europe and Australia	Reported Net Sales of $434 million (Q2 2025)

Then there are the parents and caregivers of infants. This group is served by the Nutrition category, which is dominated by the infant formula business. This segment is expected to generate approximately $360 million in net sales for 2025. To put that in perspective, that's less than 10% of the company's estimated annual net sales of $4.3 billion for 2025. Because the external environment has shifted, Perrigo Company plc is currently conducting a strategic review of this business, which includes reassessing a previously announced $240 million investment.

Finally, you have the customers seeking specialized, higher-margin self-care brands. These consumers are the target for the 'High-Grow' brands that Perrigo Company plc prioritizes investment in. In the CSCI segment, which focuses outside the U.S. and Canada, revenue generation is primarily through these national brands, such as Compeed®, Solpadeine®, and ellaOne®. These are the areas management is strengthening to drive better returns, contrasting with the cash-generating store brand business.

Finance: draft 13-week cash view by Friday.

Perrigo Company plc (PRGO) - Canvas Business Model: Cost Structure

You're looking at the hard numbers driving Perrigo Company plc's operational expenses as of late 2025. This structure is heavily influenced by manufacturing scale, ongoing efficiency programs, and necessary innovation spending.

The cost of goods sold (COGS) remains a major component, reflecting the scale of manufacturing and supply chain complexity in the consumer self-care space. For the fiscal quarter ending June 2025, the reported Cost of Sales was $666.2 million. This is reflected in the reported gross margin for the second quarter of 2025, which stood at 26.2%, with an adjusted gross margin of 28.2%. To be fair, the company is also managing potential external cost shocks; Perrigo estimated a gross increase to global COGS in 2025, beginning in the fourth quarter, of approximately $10 million to $20 million, with a full-year impact around $50 million to $60 million, potentially due to pharmaceutical tariffs.

A significant part of the current cost management focus is Project Energize, an efficiency program launched in the first quarter of 2024. This initiative is designed to reset the SG&A operating expense base and drive organizational agility. As of the second quarter of 2025, Project Energize had achieved gross annual savings of approximately $159 million since its inception, with $27 million reinvested. The program is expected to deliver total annualized pre-tax savings in the range of $140 million to $170 million by the end of 2026, with $40 million to $60 million of those savings expected to be reinvested. The associated restructuring and related charges are estimated to total between $140 million to $160 million through 2026, which includes $20 million to $40 million earmarked for capability enhancement investments.

Investment in Research and development (R&D) is necessary to fuel consumer-led innovation and maintain brand relevance. You can see the impact on operating expenses; for instance, in the second quarter of 2025, lower R&D investments provided a partial offset to the decrease in Adjusted Operating Income, alongside lower advertising and promotional (A&P) spend and Project Energize benefits. This shows a balancing act between cost discipline and necessary spending on future growth drivers like Opill® and other brand activations.

Finally, the balance sheet reflects substantial financial obligations that impact financing costs. Perrigo Company plc reported total debt of $3.65 billion as of June 28, 2025. This debt level results in an interest coverage ratio of 2.5x, with total debt at $3.65B against total assets of $10.08B. Lower interest expense from reduced debt was a positive driver for Adjusted EPS in the second quarter of 2025.

Here's a quick look at some key financial metrics impacting the cost base as of the end of Q2 2025:

Financial Metric	Amount/Value (as of June 28, 2025)
Total Debt	$3.65 billion
Cash and Cash Equivalents	$454 million
Reported Gross Margin (Q2 2025)	26.2%
Adjusted Gross Margin (Q2 2025)	28.2%
Project Energize Gross Annual Savings Achieved (to Q2 2025)	$159 million
Project Energize Reinvestment (to Q2 2025)	$27 million
Estimated Total Restructuring Charges for Project Energize	$140 million to $160 million

The ongoing commitment to Project Energize savings, alongside the management of COGS pressures and strategic R&D allocation, defines the near-term cost structure for Perrigo Company plc. Finance: draft 13-week cash view by Friday.

Perrigo Company plc (PRGO) - Canvas Business Model: Revenue Streams

Perrigo Company plc generates its revenue primarily through the sale of its Consumer Self-Care products across two main operating segments. The financial performance for the third quarter of fiscal year 2025 provides a clear snapshot of the current revenue contribution by geography.

For the third quarter of 2025, total reported net sales for Perrigo Company plc were $1,043.3 million. Year-to-date net sales through the first nine months of 2025 reached $3,143.5 million.

The segment breakdown for the third quarter of 2025 net sales is as follows:

Revenue Stream Component	Q3 2025 Net Sales Amount
Net sales from Consumer Self-Care Americas (CSCA) segment	$646 million
Net sales from Consumer Self-Care International (CSCI) segment	$398 million

The composition of the revenue mix leans heavily on private label offerings, though specific 2025 segment sales figures for private label versus branded are not explicitly broken out in the latest reports, a June 2025 presentation indicated the following revenue split:

Revenue Type	Approximate Revenue Mix (as of June 2025)
Sales of store brand/private label OTC products	60%
Sales of national/High-Grow brands	40%

Within the national/High-Grow brands category, specific products show significant momentum. For instance, the Mederma® brand (referred to as the Moderna Brand in one source) saw its net sales increase by over 35%. Conversely, the impact of the Opill® launch stocking benefit in the prior year resulted in a -0.5% drag on year-to-date 2025 organic net sales.

Perrigo Company plc has updated its expectations for the full fiscal year 2025, factoring in industry dynamics and consumption trends. The projection for the full-year 2025 net sales growth is set between -2.5% to -3.0%.

The Infant Formula business, which is currently undergoing a strategic review, was expected to generate approximately $360 million in net sales for the full year 2025, representing less than 10% of the Company's total annual net sales.

The company is focused on driving growth through its key brands, with management aiming for $100-$200 million in incremental revenue from high-growth brands by 2027.